Johnson & Johnson (JNJ.US) announced that the EGFR/c-MET bispecific "avelumab" has been approved for a new indication in the country.

On August 8th, Johnson & Johnson (JNJ.US) announced that the EGFR/c-MET dual antibody "Amivantamab" has been approved for a new indication in China, in combination with Osimertinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in adult patients with EGFR exon 19 deletions or L858R substitutions. In February 2025, the drug was first approved in China for the first-line treatment of EGFRex20ins mutation NSCLC. In April 2025, the drug was approved for a new indication in China, in combination with chemotherapy for the treatment of patients with locally advanced or metastatic NSCLC after EGFR-TKI treatment. This is the third indication for Amivantamab approved in China. Amivantamab was first granted accelerated approval for market in the United States in May 2021. To date, with a focus on non-small cell lung cancer, Amivantamab has been approved for four indications worldwide.